Sclerosis News and Research

RSS

Fast Forward selects IntraLinks to support its funding effort

IntraLinks®, the leading provider of critical information exchange solutions, today announced that Fast Forward™ has selected IntraLinks to help streamline the collection, distribution and tracking of information to support their funding of multiple biotechnology and pharmaceutical companies working on new Multiple Sclerosis (MS) treatments.

28 Aug 2009

Town halls: Even tempers prevail in Wisconsin, but not Phoenix

In Eau Claire, Wisconsin, Rep. Ron Kind, D-Wis, encountered something Democrats may have become unaccustomed to: "a fairly even-tempered crowd" at an "intimate" town hall meeting, Roll Call reports. Kind voted against the reform proposal in the House Ways and Means Committee, but defended current incarnations of the overhaul package during a meeting with local business owners and state National Federation of Independent Business representatives.

28 Aug 2009

American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

American Scientific Resources, Inc. (Pink Sheets: ASFX) (the Company), today confirmed that it has signed a letter of intent to acquire the intellectual property to the Disintegrator home needle destruction device (NDD) (U.S. Patent No. 6,384,362 Patent Application No.: 09/500,504).

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Sen. Edward M. Kennedy -- health care champion -- dies

Sen. Edward M. Kennedy had a hand in nearly every piece of health care legislation that moved through Congress during his eight-term Senate tenure. He died Tuesday night of brain cancer at age 77.

27 Aug 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

Australian researchers to discover proteins that cause multiple sclerosis

Australian researchers will aim to discover the proteins that cause multiple sclerosis (MS), thanks to a new nationwide research effort. The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.

26 Aug 2009

Veterans receive false health scare

USA Today reports: "More than 1,800 Gulf War veterans were sent letters from the Veterans Administration this month informing them that they had Lou Gehrig's disease — a fatal neurological disease. But at least some of the letters — and the diagnoses — were a mistake."

26 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Lpath, Inc., the category leader in lipidomics-based therapeutics, demonstrated commercially acceptable yields in its optimized fermentation process. In doing so, Lpath achieved one of four Phase 1 objectives established by Merck Serono, the exclusive worldwide licensee of ASONEP and Lpath's development partner, and will receive a milestone payment according to the terms of the Merck Serono license agreement.

25 Aug 2009

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The company expects to begin Phase I clinical studies in 2010.

24 Aug 2009

The California Chronic Care Coalition launches new website to share information on chronic conditions

The California Chronic Care Coalition (CCCC) continues to advance its work toward meaningful and responsible health care reform with the launching of its consumer website: www.chroniccareca.org. Designed to help build a healthier California, the website is aimed at the more than 16 million Californians with chronic conditions such as Asthma, Diabetes, Alzheimer’s Heart disease, Epilepsy and Multiple Sclerosis.

24 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Real Americans share experiences, common need for patient-centric reform

Teva Pharmaceuticals USA, the world's leading generic pharmaceutical company, today announced the start of its "Patient First" project as part of the Year of Affordable Healthcare campaign. The initiative, available at: www.yearofaffordablehealth.com/patients, features a first-hand perspective of everyday Americans as they struggle with the enormous and sometimes insurmountable expense of paying for their prescription medicines.

21 Aug 2009

IBISS research group's project aims to examine Ribavirin role in promoting the survival of transplanted stem cells

Hard to Treat Diseases (HTDS.PK) Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem reported that IBISS research group from Serbia has begun preliminary experiments within a project aimed at Promoting stem cell graft survival in the model of traumatic brain injury in rats.

20 Aug 2009

ACE inhibitors and AT1R blockers suppress inflammation in mice

Conventional blood pressure medication can treat inflammation in an animal model mimicking multiple sclerosis (MS). This discovery was made by Dr. Michael Platten, head consultant at the department of Neurooncology at Heidelberg University Hospital and head of the Helmholtz Experimental Neuroimmunology Junior Research Group on at the German Cancer Research Center and his team in cooperation with scientists from Stanford University in California.

19 Aug 2009

Smoking increases risk for brain shrinkage in multiple sclerosis

People who smoke and have multiple sclerosis (MS) may be at increased risk of brain shrinkage and increased brain lesions related to the disease, according to a study published in the August 18, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology. Smoking has already been linked to an increased risk of developing MS.

18 Aug 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009